The vascular allografts market size has grown strongly in recent years. It will grow from $1.84 billion in 2025 to $1.97 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to limited availability of donor grafts, reliance on traditional surgical techniques, growing cardiovascular disease prevalence, increasing hospital infrastructure, early adoption of cortical and cancellous grafts.
The vascular allografts market size is expected to see strong growth in the next few years. It will grow to $2.58 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to advancements in graft preservation and processing technologies, rising minimally invasive vascular procedures, growth in transplant surgeries, increasing use of composite and polymer-based materials, expansion of research and academic institutions in regenerative medicine. Major trends in the forecast period include rising demand for vascular allografts in cardiovascular surgeries, increased use of cortical and cancellous allografts, adoption of fresh frozen and freeze-dried grafts, expansion of peripheral vascular and transplant surgeries, focus on biologic and composite material innovations.
The rising prevalence of cardiovascular diseases is expected to drive the growth of the vascular allografts market in the coming years. Cardiovascular diseases encompass a group of disorders affecting the heart and blood vessels, including conditions such as coronary heart disease, heart failure, stroke, and hypertension. This increase is primarily linked to poor dietary habits, as excessive consumption of saturated fats, trans fats, added sugars, and sodium contributes to high blood pressure, obesity, and elevated cholesterol levels. Vascular allografts support cardiovascular disease treatment by providing ready-to-use donor blood vessels, making them suitable for patients with damaged or diseased vessels. They enhance surgical outcomes by restoring proper blood flow, reducing complications, and promoting long-term cardiovascular health. For example, in December 2024, GOV.UK, a UK-based government agency, reported that in March 2024, nearly 2.24 million adults in England - approximately 4.4% of those aged 18 and above - had a GP-recorded diagnosis of chronic kidney disease (CKD), up from 2.09 million cases the previous year. Therefore, the rising prevalence of cardiovascular diseases is driving growth in the vascular allografts market.
Key players in the vascular allografts market are focusing on developing advanced products, such as bioengineered graft materials, to improve graft durability, biocompatibility, and integration with host tissue. Bioengineered graft materials are specially designed vascular grafts created using advanced biological and engineering techniques. For instance, in February 2025, Humacyte Inc., a US-based biotechnology company, launched Symvess, a bioengineered vascular graft designed for adults requiring urgent revascularization due to extremity arterial injuries when autologous vein grafts are not an option. Symvess is engineered to remodel into the patient’s own tissue over time, reducing the risk of rejection and improving long-term outcomes. This graft also minimizes the need for immunosuppressive drugs, offering significant advantages in trauma and emergency surgical settings.
In May 2025, MTF Biologics, a US-based nonprofit organization, partnered with Kolosis BIO LLC to introduce innovative allograft products. This collaboration aims to expand access to advanced allograft solutions, improve surgical outcomes, and provide surgeons with high-quality, ready-to-use grafts for complex vascular and orthopedic procedures. Kolosis BIO LLC, based in the US, specializes in the development and commercialization of vascular allograft products.
Major companies operating in the vascular allografts market are Medtronic plc, Boston Scientific Corporation, Terumo Corporation, W. L. Gore & Associates Inc., Dentsply Sirona Inc., Integra LifeSciences Holdings Corporation, MicroPort Scientific Corporation, Bioventus Inc., KLS Martin Group, MTF Biologics, MTF Biologics, ZimVie Inc., B. Braun Melsungen AG, Artivion Inc., MiMedx Group Inc., RTI Surgical Inc, LeMaitre Vascular Inc., LifeNet Health Inc., Xtant Medical Holdings Inc., Osteogenics Biomedical Inc.
North America was the largest region in the vascular allografts market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vascular allografts market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vascular allografts market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the vascular allografts market by increasing the cost of imported graft materials and processing equipment. Segments like cortical and corticocancellous allografts are particularly impacted, with regions such as Asia-Pacific, including China and India, facing higher import duties. This has led to increased production costs and potential delays in supply chains. However, tariffs have also encouraged local production, investment in domestic graft processing facilities, and innovation in biologic and composite materials, providing a positive long-term effect on market self-reliance.
The vascular allografts market research report is one of a series of new reports that provides vascular allografts market statistics, including vascular allografts industry global market size, regional shares, competitors with a vascular allografts market share, detailed vascular allografts market segments, market trends and opportunities, and any further data you may need to thrive in the vascular allografts industry. This vascular allografts market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Vascular allografts are blood vessels harvested from a human donor and transplanted into another patient to replace or bypass damaged or diseased vessels. They are used to restore blood flow in cases where a patient’s own vessels are unsuitable for grafting, such as during bypass surgeries or vascular reconstruction.
The primary types of vascular allografts include cortical allografts, cancellous allografts, and corticocancellous allografts. Cortical allografts are derived from the dense outer layer of donor bone and are used to provide structural support and promote bone healing in orthopedic and dental procedures. These allografts utilize materials such as biologic, synthetic, composite, and polymer-based materials, and find applications in cardiovascular surgery, peripheral vascular surgery, transplant surgery, and repair of congenital defects. Distribution channels include direct sales, online platforms, distributors, and medical supply stores, catering to end-users such as hospitals, ambulatory surgical centers (ASCs), specialty clinics, and research and academic institutions.
The vascular allografts market consists of sales of arterial allografts, venous allografts, cryopreserved vascular grafts, fresh vascular grafts, and decellularized vascular allografts. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The vascular allografts market size is expected to see strong growth in the next few years. It will grow to $2.58 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to advancements in graft preservation and processing technologies, rising minimally invasive vascular procedures, growth in transplant surgeries, increasing use of composite and polymer-based materials, expansion of research and academic institutions in regenerative medicine. Major trends in the forecast period include rising demand for vascular allografts in cardiovascular surgeries, increased use of cortical and cancellous allografts, adoption of fresh frozen and freeze-dried grafts, expansion of peripheral vascular and transplant surgeries, focus on biologic and composite material innovations.
The rising prevalence of cardiovascular diseases is expected to drive the growth of the vascular allografts market in the coming years. Cardiovascular diseases encompass a group of disorders affecting the heart and blood vessels, including conditions such as coronary heart disease, heart failure, stroke, and hypertension. This increase is primarily linked to poor dietary habits, as excessive consumption of saturated fats, trans fats, added sugars, and sodium contributes to high blood pressure, obesity, and elevated cholesterol levels. Vascular allografts support cardiovascular disease treatment by providing ready-to-use donor blood vessels, making them suitable for patients with damaged or diseased vessels. They enhance surgical outcomes by restoring proper blood flow, reducing complications, and promoting long-term cardiovascular health. For example, in December 2024, GOV.UK, a UK-based government agency, reported that in March 2024, nearly 2.24 million adults in England - approximately 4.4% of those aged 18 and above - had a GP-recorded diagnosis of chronic kidney disease (CKD), up from 2.09 million cases the previous year. Therefore, the rising prevalence of cardiovascular diseases is driving growth in the vascular allografts market.
Key players in the vascular allografts market are focusing on developing advanced products, such as bioengineered graft materials, to improve graft durability, biocompatibility, and integration with host tissue. Bioengineered graft materials are specially designed vascular grafts created using advanced biological and engineering techniques. For instance, in February 2025, Humacyte Inc., a US-based biotechnology company, launched Symvess, a bioengineered vascular graft designed for adults requiring urgent revascularization due to extremity arterial injuries when autologous vein grafts are not an option. Symvess is engineered to remodel into the patient’s own tissue over time, reducing the risk of rejection and improving long-term outcomes. This graft also minimizes the need for immunosuppressive drugs, offering significant advantages in trauma and emergency surgical settings.
In May 2025, MTF Biologics, a US-based nonprofit organization, partnered with Kolosis BIO LLC to introduce innovative allograft products. This collaboration aims to expand access to advanced allograft solutions, improve surgical outcomes, and provide surgeons with high-quality, ready-to-use grafts for complex vascular and orthopedic procedures. Kolosis BIO LLC, based in the US, specializes in the development and commercialization of vascular allograft products.
Major companies operating in the vascular allografts market are Medtronic plc, Boston Scientific Corporation, Terumo Corporation, W. L. Gore & Associates Inc., Dentsply Sirona Inc., Integra LifeSciences Holdings Corporation, MicroPort Scientific Corporation, Bioventus Inc., KLS Martin Group, MTF Biologics, MTF Biologics, ZimVie Inc., B. Braun Melsungen AG, Artivion Inc., MiMedx Group Inc., RTI Surgical Inc, LeMaitre Vascular Inc., LifeNet Health Inc., Xtant Medical Holdings Inc., Osteogenics Biomedical Inc.
North America was the largest region in the vascular allografts market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vascular allografts market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vascular allografts market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the vascular allografts market by increasing the cost of imported graft materials and processing equipment. Segments like cortical and corticocancellous allografts are particularly impacted, with regions such as Asia-Pacific, including China and India, facing higher import duties. This has led to increased production costs and potential delays in supply chains. However, tariffs have also encouraged local production, investment in domestic graft processing facilities, and innovation in biologic and composite materials, providing a positive long-term effect on market self-reliance.
The vascular allografts market research report is one of a series of new reports that provides vascular allografts market statistics, including vascular allografts industry global market size, regional shares, competitors with a vascular allografts market share, detailed vascular allografts market segments, market trends and opportunities, and any further data you may need to thrive in the vascular allografts industry. This vascular allografts market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Vascular allografts are blood vessels harvested from a human donor and transplanted into another patient to replace or bypass damaged or diseased vessels. They are used to restore blood flow in cases where a patient’s own vessels are unsuitable for grafting, such as during bypass surgeries or vascular reconstruction.
The primary types of vascular allografts include cortical allografts, cancellous allografts, and corticocancellous allografts. Cortical allografts are derived from the dense outer layer of donor bone and are used to provide structural support and promote bone healing in orthopedic and dental procedures. These allografts utilize materials such as biologic, synthetic, composite, and polymer-based materials, and find applications in cardiovascular surgery, peripheral vascular surgery, transplant surgery, and repair of congenital defects. Distribution channels include direct sales, online platforms, distributors, and medical supply stores, catering to end-users such as hospitals, ambulatory surgical centers (ASCs), specialty clinics, and research and academic institutions.
The vascular allografts market consists of sales of arterial allografts, venous allografts, cryopreserved vascular grafts, fresh vascular grafts, and decellularized vascular allografts. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Vascular Allografts Market Characteristics
3. Vascular Allografts Market Supply Chain Analysis
4. Global Vascular Allografts Market Trends and Strategies
5. Vascular Allografts Market Analysis of End Use Industries
7. Global Vascular Allografts Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Vascular Allografts Total Addressable Market (TAM) Analysis for the Market
9. Vascular Allografts Market Segmentation
10. Vascular Allografts Market Regional and Country Analysis
11. Asia-Pacific Vascular Allografts Market
12. China Vascular Allografts Market
13. India Vascular Allografts Market
14. Japan Vascular Allografts Market
15. Australia Vascular Allografts Market
16. Indonesia Vascular Allografts Market
17. South Korea Vascular Allografts Market
18. Taiwan Vascular Allografts Market
19. South East Asia Vascular Allografts Market
20. Western Europe Vascular Allografts Market
21. UK Vascular Allografts Market
22. Germany Vascular Allografts Market
23. France Vascular Allografts Market
24. Italy Vascular Allografts Market
25. Spain Vascular Allografts Market
26. Eastern Europe Vascular Allografts Market
27. Russia Vascular Allografts Market
28. North America Vascular Allografts Market
29. USA Vascular Allografts Market
30. Canada Vascular Allografts Market
31. South America Vascular Allografts Market
32. Brazil Vascular Allografts Market
33. Middle East Vascular Allografts Market
34. Africa Vascular Allografts Market
36. Vascular Allografts Market Competitive Landscape and Company Profiles
37. Vascular Allografts Market Other Major and Innovative Companies
40. Vascular Allografts Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Vascular Allografts Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses vascular allografts market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for vascular allografts? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The vascular allografts market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Cortical Allograft; Cancellous Allograft; Corticocancellous Allograft2) By Material Type: Biologic Materials; Synthetic Materials; Composite Materials; Polymer-Based Materials
3) By Application: Cardiovascular Surgery; Peripheral Vascular Surgery; Transplant Surgery; Repair Of Congenital Defects
4) By Distribution Channel: Direct Sales; Online Sales; Distributors; Medical Supply Stores
5) By End-User: Hospitals; Ambulatory Surgical Centers (ASCs); Specialty Clinics; Research And Academic Institutions
Subsegments:
1) By Cortical Allograft: Structural Cortical Allografts; Segmental Cortical Allografts; Shaped Cortical Allografts; Machined Cortical Allografts2) By Cancellous Allograft: Granular Cancellous Allografts; Block Cancellous Allografts; Molded Cancellous Allografts; Injectable Cancellous Allografts
3) By Corticocancellous Allograft: Composite Corticocancellous Allografts; Block Corticocancellous Allografts; Shaped Corticocancellous Allografts; Structural Corticocancellous Allografts
Companies Mentioned: Medtronic plc; Boston Scientific Corporation; Terumo Corporation; W. L. Gore & Associates Inc.; Dentsply Sirona Inc.; Integra LifeSciences Holdings Corporation; MicroPort Scientific Corporation; Bioventus Inc.; KLS Martin Group; MTF Biologics; MTF Biologics; ZimVie Inc.; B. Braun Melsungen AG; Artivion Inc.; MiMedx Group Inc.; RTI Surgical Inc; LeMaitre Vascular Inc.; LifeNet Health Inc.; Xtant Medical Holdings Inc.; Osteogenics Biomedical Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Vascular Allografts market report include:- Medtronic plc
- Boston Scientific Corporation
- Terumo Corporation
- W. L. Gore & Associates Inc.
- Dentsply Sirona Inc.
- Integra LifeSciences Holdings Corporation
- MicroPort Scientific Corporation
- Bioventus Inc.
- KLS Martin Group
- MTF Biologics
- MTF Biologics
- ZimVie Inc.
- B. Braun Melsungen AG
- Artivion Inc.
- MiMedx Group Inc.
- RTI Surgical Inc
- LeMaitre Vascular Inc.
- LifeNet Health Inc.
- Xtant Medical Holdings Inc.
- Osteogenics Biomedical Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.97 Billion |
| Forecasted Market Value ( USD | $ 2.58 Billion |
| Compound Annual Growth Rate | 7.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
